IMUNON said Wednesday that Stacy Lindborg has been named CEO and president, effective Monday. Lindborg has served on IMUNON’s board of directors since 2021.
Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on research & development, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity.
The Lawrenceville-based clinical-stage drug development company said it looks forward to benefiting from Lindborg’s expertise in a new and deeper capacity, especially as its near-term data readouts will require important decisions with respect to advancing various programs and assets.
Lindborg joins IMUNON from BrainStorm Cell Therapeutics, where she was co-CEO and executive vice president, and where she remains a member of the board of directors. At BrainStorm, she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.
Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the company’s Phase 2 OVATION 2 Study in advanced ovarian cancer are expected by midsummer.
“Dr. Lindborg is uniquely qualified to take the reins as IMUNON’s president and CEO, bringing a track record of success in virtually every aspect of the work before the company,” Michael Tardugno, IMUNON’s executive chairman, said. “Her ability to navigate global regulatory paths, having successfully delivered products from the clinic to the market, will be valuable to IMUNON as our pipeline advances. We have benefited significantly from her counsel as a director, where she has played an integral role in establishing our strategic priorities.”
“I have enjoyed being close to the emerging science during the development of our IL-12 therapy TheraPlas and our PlaCCine modalities, in addition to getting to know the depth of talent in the company. I am thrilled to assume direct managerial responsibilities as we work to bring these important products and technologies to patients. I am also excited by the prospect of creating shareholder value as we determine the next steps for our platform products,” Lindborg said.
